30 June 2023
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Annual General Meeting
Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
| Ordinary Resolutions | Votes for | % of votes cast for | Votes Against | % of votes cast against | Total votes cast | Total votes cast as % of ISC (1) | Votes with-held (2) |
| 1. To adopt the 2022 Annual Report and Accounts | 187,231,295 | 99.86 | 260,529 | 0.14 | 187,491,824 | 16.42 | 4,905,675 |
| 2. To approve the Directors' Remuneration Policy | 175,511,893 | 91.34 | 16,644,001 | 8.66 | 192,155,894 | 16.83 | 241,605 |
| 3. To re-appoint Peter Redmond as Director | 161,957,826 | 86.38 | 25,531,232 | 13.62 | 187,489,058 | 16.42 | 4,908,441 |
| 4. To re-appoint Alexis Sandler as Director | 175,078,447 | 93.44 | 12,285,451 | 6.56 | 187,363,898 | 16.41 | 5,033,601 |
| 5. To re-appoint Dr Vladislav Sandler as Director | 175,160,284 | 93.49 | 12,203,614 | 6.51 | 187,363,898 | 16.41 | 5,033,601 |
| 6. To reappoint the Company's auditor | 185,776,647 | 99.09 | 1,715,177 | 0.91 | 187,491,824 | 16.42 | 4,905,675 |
| 7. To authorise the Audit Committee to determine the auditor's remuneration | 176,309,143 | 94.04 | 11,179,915 | 5.96 | 187,489,058 | 16.42% | 4,908,441 |
| 8. To authorise the Directors to allot equity securities | 170,229,487 | 90.79 | 17,259,571 | 9.21 | 187,489,058 | 16.42 | 4,908,441 |
| Special Resolutions | Votes for | % of votes cast for | Votes against | % of votes cast against | Total votes cast | Total votes cast as % of ISC (1) | Votes with-held (2) |
| 9. To disapply pre-emption provisions | 156,025,169 | 89.79 | 17,751,132 | 10.21 | 173,776,301 | 15.22 | 18,621,198 |
| 10. To reduce the notice period for general meetings | 171,582,521 | 91.51 | 15,909,303 | 8.49 | 187,491,824 | 16.42 | 4,905,675 |
(1) The Company's issued share capital ("ISC") on 28 June 2023, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,141,999,321 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
| Hemogenyx Pharmaceuticals plc | |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
| Peter Redmond, Director | |
|
|
|
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
|
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
